BACKGROUND: Diaphragmatic hernias after esophagectomy are mostly asymptomatic. However, they can also manifest with severe complications and be associated with high morbidity and mortality rates. The aims of this study were to assess the incidence, predictive factors, and preferred treatment of symptomatic diaphragmatic hernias and to evaluate the role of prophylactic cruroplasty in patients after esophagectomy for carcinomas of the esophagus or gastroesophageal junction. METHODS: A prospective database was used to retrospectively analyze consecutive patients who underwent esophagectomy between January 2005 and December 2015. RESULTS: A symptomatic diaphragmatic hernia was diagnosed in 21 (2.5%) of 851 included patients; 15 (4.3%) after 345 minimally invasive esophagectomies and 6 (1.2%) after 506 open esophagectomies (p = 0.004). Minimally invasive Ivor Lewis procedures had the highest incidence (9.4%; p = 0.002) as compared with all other procedures. Prophylactic cruroplasty did not decrease the incidence of symptomatic diaphragmatic hernias (2.1% vs 2.7%; p = 0.608). Surgical treatment consisted of cruroplasty, with reinforcement of Prolene pledgets (Ethicon, Somerville, NJ) in 11 patients. Major complications (Clavien-Dindo grade >IIIb) occurred in 3 patients, all after open repair (n = 9). Recurrences were found in 4 patients (19.0%), three after laparoscopic repair and one after open repair. CONCLUSIONS: The incidence of symptomatic diaphragmatic hernia after esophagectomy was 2.5%, with the highest incidence after minimally invasive Ivor Lewis esophagectomy (9.4%) as compared with other procedures. Although prophylactic cruroplasty is now the standard of care in patients undergoing minimally invasive esophagectomy, a significant lower hernia rate was not found in this study.
BACKGROUND:Diaphragmatic hernias after esophagectomy are mostly asymptomatic. However, they can also manifest with severe complications and be associated with high morbidity and mortality rates. The aims of this study were to assess the incidence, predictive factors, and preferred treatment of symptomatic diaphragmatic hernias and to evaluate the role of prophylactic cruroplasty in patients after esophagectomy for carcinomas of the esophagus or gastroesophageal junction. METHODS: A prospective database was used to retrospectively analyze consecutive patients who underwent esophagectomy between January 2005 and December 2015. RESULTS: A symptomatic diaphragmatic hernia was diagnosed in 21 (2.5%) of 851 included patients; 15 (4.3%) after 345 minimally invasive esophagectomies and 6 (1.2%) after 506 open esophagectomies (p = 0.004). Minimally invasive Ivor Lewis procedures had the highest incidence (9.4%; p = 0.002) as compared with all other procedures. Prophylactic cruroplasty did not decrease the incidence of symptomatic diaphragmatic hernias (2.1% vs 2.7%; p = 0.608). Surgical treatment consisted of cruroplasty, with reinforcement of Prolene pledgets (Ethicon, Somerville, NJ) in 11 patients. Major complications (Clavien-Dindo grade >IIIb) occurred in 3 patients, all after open repair (n = 9). Recurrences were found in 4 patients (19.0%), three after laparoscopic repair and one after open repair. CONCLUSIONS: The incidence of symptomatic diaphragmatic hernia after esophagectomy was 2.5%, with the highest incidence after minimally invasive Ivor Lewis esophagectomy (9.4%) as compared with other procedures. Although prophylactic cruroplasty is now the standard of care in patients undergoing minimally invasive esophagectomy, a significant lower hernia rate was not found in this study.